Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,023 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tryptophan degradation as a systems phenomenon in inflammation - an analysis across 13 chronic inflammatory diseases.
Harris DMM, Szymczak S, Schuchardt S, Labrenz J, Tran F, Welz L, Graßhoff H, Zirpel H, Sümbül M, Oumari M, Engelbogen N, Junker R, Conrad C, Thaçi D, Frey N, Franke A, Weidinger S, Hoyer B, Rosenstiel P, Waschina S, Schreiber S, Aden K. Harris DMM, et al. Among authors: conrad c. EBioMedicine. 2024 Apr;102:105056. doi: 10.1016/j.ebiom.2024.105056. Epub 2024 Mar 11. EBioMedicine. 2024. PMID: 38471395 Free PMC article.
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S. Zeissig S, et al. Among authors: conrad c. Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5. Gut. 2019. PMID: 29730603
Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19.
Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, Dargvainiene J, Schröder I, Wieters I, Khodamoradi Y, Eberhardt F, Vehreschild MJGT, Neb H, Sonntagbauer M, Conrad C, Tran F, Rosenstiel P, Markewitz R, Wandinger KP, Augustin M, Rybniker J, Kochanek M, Leypoldt F, Cornely OA, Koehler P, Franke A, Scheffold A. Bacher P, et al. Among authors: conrad c. Immunity. 2020 Dec 15;53(6):1258-1271.e5. doi: 10.1016/j.immuni.2020.11.016. Epub 2020 Nov 26. Immunity. 2020. PMID: 33296686 Free PMC article.
Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy.
Ellrichmann M, Bethge J, Boesenkoetter J, Conrad C, Noth R, Bahmer T, Nikolaus S, Aden K, Zeissig S, Schreiber S. Ellrichmann M, et al. Among authors: conrad c. J Crohns Colitis. 2021 Aug 2;15(8):1339-1345. doi: 10.1093/ecco-jcc/jjab024. J Crohns Colitis. 2021. PMID: 33544122 Free PMC article.
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F, Rose-John S, Waetzig GH, Rosenstiel P. Schreiber S, et al. Among authors: conrad c. Gastroenterology. 2021 Jun;160(7):2354-2366.e11. doi: 10.1053/j.gastro.2021.02.062. Epub 2021 Mar 2. Gastroenterology. 2021. PMID: 33667488 Free article. Clinical Trial.
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, Conrad C, Avalos D, Jaeckel C, Scherer M, Sørensen SB, Overgaard SH, Schulte B, Nikolaus S, Rey G, Gasparoni G, Lyons PA, Schultze JL, Walter J, Andersen V; SYSCID Consortium; Dermitzakis ET, Schreiber S, Rosenstiel P. Mishra N, et al. Among authors: conrad c. Genome Med. 2022 Sep 24;14(1):110. doi: 10.1186/s13073-022-01112-z. Genome Med. 2022. PMID: 36153599 Free PMC article.
ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis.
Cerminara SE, Cvijetic I, Huber S, Müller S, Kostner L, Goessinger EV, Narainsing J, Dutilh G, Heidemeyer K, Yawalkar N, Conrad C, Plaza T, Maul JT, Cozzio A, Navarini AA. Cerminara SE, et al. Among authors: conrad c. J Eur Acad Dermatol Venereol. 2024 Oct 24. doi: 10.1111/jdv.20400. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39445679 No abstract available.
1,023 results